Company overview
Company overview
Kither Biotech is a clinical-stage biotech company developing novel inhaled therapies for respiratory diseases with high unmet medical need.
The company is advancing a differentiated pipeline of localized pulmonary therapies designed to modulate disease-relevant intracellular signaling pathways involved in inflammation, airway narrowing, mucus obstruction, and fibrotic remodeling. Kither’s approach combines targeted lung delivery with multi-modal pharmacology to address the pathological complexity of multiple respiratory diseases through a single therapeutic platform.
Kither’s lead candidate, KIT2014, is an inhaled cAMP-modulating peptide currently being advanced toward Phase 2 clinical development in chronic obstructive pulmonary disease (COPD), following the successful completion of a first-in-human Phase 1 study in healthy volunteers. Beyond COPD, the balanced and dual PDE3/4 inhibition of KIT2014 has potential to treat a range of serious respiratory indications and improve the lives of those living with non-cystic fibrosis bronchiectasis (NCFBE), idiopathic pulmonary fibrosis (IPF), and cystic fibrosis (CF).
The company’s pipeline also includes KITCL27, an inhaled pan-Class I PI3K inhibitor prodrug for pulmonary fibrosis, as well as next-generation compounds.